Combination treatment efficient for high astigmatism correction

Article

Combined toric lens implantation and astigmatic keratotomy is a safe and effective way to correct high astigmatism, according to findings published in Techniques in Ophthalmology.

Combined toric lens implantation and astigmatic keratotomy is a safe and effective way to correct high astigmatism, according to findings published in Techniques in Ophthalmology.

Dr Robert H. Osher et al., Cincinnati Eye Institute, Cincinnati, Ohio, USA, studied 20 eyes with keratometric astigmatism with a mean of 4.05 D. All patients were implanted with a toric IOL combined with astigmatic keratotomy. The outcome measure was uncorrected distance visual acuity (UDVA).

All patients attained a UDVA of 20/40 or better. Of the 20 eyes studied, 8 eyes achieved a UDVA of 20/25 or better and 16 eyes achieved 1 D or less of refractive cylinder. Additionally, no complications occurred either intra- or postoperatively and the full group indicated satisfaction with their visual results.

The results demonstrated that through combining toric IOL implantation and astigmatic keratotomy it is possible to reduce high astigmatism in cataract patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.